Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18-methyl–19-nortestosterone is a synthetic steroidal compound classified as an androgen and anabolic steroid. It is structurally related to nandrolone (19-nortestosterone) with a methyl group at the C18 position. The compound has been studied primarily as an experimental or reference substance and is not approved for medical use. Its mechanism of action, like other nortestosterone derivatives, involves agonism at the androgen receptor, leading to anabolic and androgenic effects. Esters and derivatives of this molecule have demonstrated progestogenic activity in animal models, including ovulation inhibition when administered orally or subcutaneously[1][2][5]. It serves as a parent structure for several clinically relevant progestins such as levonorgestrel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18-methyl-19-nortestosterone.